<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2626">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04337008</url>
  </required_header>
  <id_info>
    <org_study_id>2020-16</org_study_id>
    <secondary_id>2020-A00795-34</secondary_id>
    <nct_id>NCT04337008</nct_id>
  </id_info>
  <brief_title>Renin Angiotensin System - CoronaVirus</brief_title>
  <acronym>SRA-COV</acronym>
  <official_title>Renin Angiotensin System - CoronaVirus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to demonstrate overactivation of Renin Angiotensine System (RAS) in
      positives COVID-19 patient, especially in those with the most serious clinical forms where
      the mortality of patients in intensive care is on average 50%.

      We are expecting two groups: a group of 25 positive COVID 19 patients in intensive care and a
      group of 25 positive COVID 19 hospitalized patients in conventional hospitalisation. We will
      measure RAS, serum potassium and collect data on the treatment of these patients (especially
      antihypertensive therapy) one week apart (at the patient'entry into hospital and 7 days
      later).

      This is a preliminary study that could possibly allow the start of a therapeutic trial in
      order to test the effectiveness of RAS blocker treatments in this condition.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 3, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overactivity of the renin / aldosterone system</measure>
    <time_frame>7 days</time_frame>
    <description>demonstrate overactivity of RAS in patients hospitalised in intensive car secondary to COVID-19 compared to control patients (COVID -19 hospitalised patients without complications ).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>COVID 19</condition>
  <arm_group>
    <arm_group_label>Positive COVID 19 patient with no respiratory distress</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Positive COVID 19 patient with respiratory distress</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood draw</intervention_name>
    <description>20 mL blood draw will be performed at J1 et J7</description>
    <arm_group_label>Positive COVID 19 patient with no respiratory distress</arm_group_label>
    <arm_group_label>Positive COVID 19 patient with respiratory distress</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive COVID 19 patients hospitalized in conventionnal hospitalisation

          -  Patients hospitalized in intensive care secondary to COVID-19 : Patient under invasive
             mechanical ventilation (PaO2 / FiO2 ratio &lt;300; PEEP&gt; = 5 cmH20; PCR SARS-CoV-2
             positive in a pharyngeal or respiratory sample; PaO2 / FiO2 ratio&gt; 300)

        Exclusion Criteria:

          -  Minor patient

          -  Patient deprived of liberty

          -  Patient's refusal to participate in the study

          -  Patient for whom therapeutic limitation measures such as non-admission to intensive
             care have been issued
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emilie Garrido-Pradalie</last_name>
    <role>Study Director</role>
    <affiliation>ASSISTANCE PUBLIQUE HÔPITAUX de MARSEILLE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>François Silhol, MD</last_name>
    <email>francois.silhol@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>ASSISTANCE PUBLIQUE HÖPITAUX de MARSEILLE</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francois Silhol, MD</last_name>
      <email>francois.silhol@ap-hm.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 3, 2020</study_first_submitted>
  <study_first_submitted_qc>April 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2020</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

